Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case–control study

BMC Infectious Diseases

Anne-Mette Lebech³  Andreas Kjaer¹  Thomas Benfield³  Gitte Kronborg³  Niels Obel²  Jan Gerstoft²  Terese L Katzenstein²  Holger Jon Møller⁴  Andreas Knudsen¹ 

[1] Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Kettegaard Allé 30, Hvidovre 2650, Denmark;Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

关键词: Soluble CD163;    Myocardial infarction;    HIV-infection;   

Others  :  1148303
DOI  :  10.1186/1471-2334-13-230

 received in 2013-01-29, accepted in 2013-05-13,  发布年份 2013

【 摘 要 】

Background

Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI).

Methods

We conducted a nested case–control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case’s MI, and 4: The last sample available before the case’s MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI.

Results

The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 – 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).

Conclusion

sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.

【 授权许可】

   
2013 Knudsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, Gerstoft J: Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study. Clin Infect Dis 2007, 44:1625-1631.
• [2]Knudsen A, Kristoffersen US, Kjær A, Lebech A-M: Cardiovascular disease in patients with HIV. Future Virology 2012, 7:413-423.
• [3]Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, Grinspoon SK: Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010, 24:243-253.
• [4]Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S: The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med 2010, 153:387-395.
• [5]Aristoteli LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L: The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 2006, 184:342-347.
• [6]Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, Rosenberg ES, Williams KC, Grinspoon S: Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients. J Infect Dis 2011, 204:1227-1236.
• [7]Subramanian STA: Arterial inflammation in patients with hiv. JAMA 2012, 308:379-386.
• [8]Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sørensen HT: Cohort Profile: The Danish HIV Cohort Study. Int J Epidemiol 2009, 38:1202-1206.
• [9]Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature: Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979, 59:607-609.
• [10]Perk J, Backer GD, Gohlke H, Graham I, Reiner Ž, Verschuren WMM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Reimer WJMSO, Vrints C, Wood D, Zamorano JL, Zannad F: European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). Int J Behav Med 2012, 19:403-488.
• [11]Møller HJ, Hald K, Moestrup SK: Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scan J Clin Lab Inv 2002, 62:293-299.
• [12]Møller HJ: Soluble CD163. Scan J Clin Lab Inv 2012, 72:1-13.
• [13]Hansson GK: Inflammation, Atherosclerosis, and Coronary Artery Disease. New England J Med 2005, 352:1685-1695.
• [14]Crowe SM, Hoy JF: Are Monocytes the Canary in the Coal Mine for HIV-Related Atherosclerosis? J Infect Dis 2012, 206:1491-1493.
• [15]Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS: Biomarkers of Microbial Translocation and Macrophage Activation: Association With Progression of Subclinical Atherosclerosis in HIV-1 Infection. J Infect Dis 2012, 206:1558-1567.
• [16]Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D: HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. Clin Infect Dis 2012, 55:600-607.
• [17]Kristoffersen U, Kofoed K, Kronborg G, Giger A, Kjaer A, Lebech A: Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Medicine 2009, 10:79-87.
• [18]Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA: No Association of Abacavir Use With Myocardial Infarction. J Acquir Immune Defic Synd 2012, 61:441-447.
• [19]The SMART/INSIGHT and the D:A:D Study Groups: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008, 22:F17-F24.